SYNAIRGEN PLC — Share Issue/Capital Change 2014

Jun 12, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4986J

Synairgen plc

12 June 2014

Synairgen plc

("Synairgen" or the "Company")

Exercise of Options

Synairgen (LSE: SNG), the respiratory drug development company, announces that it has today applied for 266,363 ordinary shares of one pence each (the "Option Shares") to be admitted to trading on the AIM Market of the London Stock Exchange ("AIM") ("Admission"). It is expected that Admission will occur and that dealings will commence in the Option Shares on 18 June 2014.

The Options Shares are being issued pursuant to the exercise of options by employees of the Company. The Options Shares will rank pari passu with the Company's existing ordinary shares.

Following Admission, the number of Ordinary Shares in issue and admitted to trading on AIM will be 78,587,254.

Contact

Synairgen plc Richard Marsden, CEO John Ward, Finance Director	+44 (0)23 8051 2800
finnCap Ltd Geoff Nash Christopher Raggett	+44 (0)20 7220 0500
Newgate Threadneedle Graham Herring Josh Royston	+44 (0)20 7653 9850

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCQKBDKBBKDFAD